Contact

Our portfolio

AlpENa Biosciences

Innovating cancer therapeutics, AlpENa Biosciences develops bispecific antibodies that activate immune cells to target and destroy tumor cells. Their research, based on the work of Professor Marjolein van Egmond, shows promising potential in a variety of oncology treatments. The company is backed by Versant Ventures in order to advance these therapies.

  • Institute: Amsterdam UMC
Industry: Oncology, Therapeutics
  • Founding year: 2023
Visit website

Want to get in contact about AlpENa Biosciences?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Skyline Dx
Advancing molecular diagnostics for precision oncology and infectious diseases.
Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis.
Pepper Therapeutics
Repurposing the obsolete diabetes drug phenformin into an affordable and widely available therapy for pancreatic cancer
Phlox Therapeutics
Developing RNA-based therapies for rare genetic heart diseases.
Skyline Dx
Advancing molecular diagnostics for precision oncology and infectious diseases.
Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis.
Pepper Therapeutics
Repurposing the obsolete diabetes drug phenformin into an affordable and widely available therapy for pancreatic cancer
Phlox Therapeutics
Developing RNA-based therapies for rare genetic heart diseases.
Explore full AAV portfolio
Contact